- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02454439
Assessment of Cardiac Resynchronization Therapy in Patients With Wide QRS and Non-specific Intraventricular Conduction Delay: a Randomized Trial (NICD-CRT)
The aim of the NICD-CRT study is to assess whether CRT may be clinically beneficial in HF patients with NICD and reduced ejection fraction on 12-month HF status.
In effect, the effectiveness of cardiac resynchronization therapy in heart failure (HF) with reduced ejection fraction patients with non specific intraventricular conduction delay (NICD) has never been confirmed even if it is recommended.
At the moment, no dedicated study has already been performed to assess the benefit of CRT in patients with NICD. Results from CRT therapy are contradictory in this patient group and have only been obtained from subgroup analysis. Some of them don't show clinical benefit but others show a benefit in term of an end-diastolic and/or end-systolic left ventricular volume (decrease of the size and the volumes of left ventricule).
The AHA/ACCF guidelines, published in 2005 and updated in 2009, considered only QRS duration (≥120 ms) for the indication of CRT implantation, without any consideration for the type of conduction disorder (i.e. LBBB vs. non-LBBB), current updated 2012 ACCF/AHA/HRS guidelines, consider QRS morphology (i.e. LBBB) as the first step for CRT candidate selection in addition to QRS duration (>150 ms). Indications for resynchronization have been restricted since indication of CRT in non-LBBB patients (e.g. NICD) is only a class IIa (>150 ms, only in NYHA III and ambulatory IV; level of evidence A). The same modifications have been applied between 2011 and 2013 in the European guidelines. None is known about patients with NICD and QRS > 130 ms.
Study Overview
Detailed Description
This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
• Patients will be included in thirteen sites in France(Clermont-Ferrand University Hospital, Côte Basque Hospital, Bordeaux University Hospital, Saint-Augustin Clinic, Limoges University Hospital, Grenoble University Hospital, Nantes University Hospital, Nantes New Clinic, Rennes University Hospital, Saint-Etienne University Hospital, Tours University Hospital, Toulouse University Hospital, Georges Pompidou European Hospital) and two sites in the Netherlands (Maastricht University Hospital and Radboud University Medical Center)
- At baseline a preimplantation evaluation is performed: clinical examination, ECG, six minute walk test, biology analysis, quality of life assessment, echocardiography, peak oxygen consumption.
At 6 months, evaluation of efficacy which is the secondary assessment criteria:
- Quality of life: Minnesota Living With Heart Failure Questionnary: MLWHFQ) : improvement of at least 20 points
Functionnal capacity :
- NYHA classification reduction ≥ 1 class,
- 6-minute walk test improvement of at least 10 % in distance,
- Peak oxygen consumption increased by 1.0 ml/kg/minNYHA response to CRT is the primary endpoint. It is a composite primary endpoint, including modification of: Quality of Life Score (MINNESOTA scale), NYHA functional status , 6-minute walk test and volume of the left ventricle.
- Percentage of hospitalizations for HF, for cardiovascular reasons and for all causes Decrease >15% in end-diastolic and/or end-systolic volumes of the left ventricle.
- At 12 months, comparison of the proportion of improved, unchanged and worsend patients (Packer Score) in both group which is the primary endpoint and new evaluation of the CRT efficacy (same as 6 months)and comparison of the death and percentage of hospitalization in both group which is the primary endpoint.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Gérald GOUBY
- Phone Number: 04 73 75 49 62
- Email: ggouby@chu-clermontferrand.fr
Study Locations
-
-
-
Clermont-Ferrand, France, 63003
- Recruiting
- CHU Clermont-Ferrand
-
Contact:
- Gérald GOUBY
- Phone Number: 04 73 75 49 62
- Email: ggouby@chu-clermontferrand.fr
-
Principal Investigator:
- Romain Eschalier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria :
- Patients over 18 years' old
- NYHA class II to IV ambulatory
- QRS duration > 130 ms
- Patients with sinus rhythm
- LVEF < 35%
QRS morphology: NICD according to the AHA/ACCF/HRS Recommendations (non-LBBB and non-RBBB):
- Not broad notched or slurred R wave in leads I, aVL, V5 and V6;
- Presence of a Q wave in leads I, V5, V6;
- No rsr', rsR' or rSR' pattern in leads V1 or V2.
- Life expectancy expected to exceed one year with a good functional status
- Optimal pharmacological therapy of heart failure according to clinician
Non inclusion criteria :
- Inability to understand nor decline the study,
- Impaired mobility,
- Unable to fill out questionnaire independently,
- Patients with permanent atrial fibrillation,
- Pregnant women,
- Dependant adult,
- Patients minor,
- Life expectancy < 1 year due to other causes than HF.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CRT-D or CRT-P ON
This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
|
|
Other: CRT-D or CRT-P OFF
This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite of 2 clinical endpoints combined (12 months all-cause deaths and percentage of hospitalizations for HF at 12 months) combined using an average z-score.
Time Frame: at 12 months
|
According to z-score
|
at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of efficacy, analysis of 12- month deaths
Time Frame: at 6 and 12 months
|
HF, cardiovascular and all causes deaths
|
at 6 and 12 months
|
Evaluation of efficacy, analysis of - Quality-of-life questionnaires
Time Frame: at 6 and 12 months
|
Minnesota Living With Heart Failure Questionnaire: MLWHFQ): improvement of at least 20 points
|
at 6 and 12 months
|
Evaluation of efficacy, analysis of Functional capacity
Time Frame: at 6 and 12 months
|
NYHA classification reduction ≥ 1 class, 6-minute walk test improvement of at least 10 % in distance, Peak oxygen consumption increased by 1.0 ml/kg/min
|
at 6 and 12 months
|
Evaluation of efficacy, analysis of Percentage of hospitalizations for HF
Time Frame: at 6 and 12 months
|
at 6 and 12 months
|
|
Evaluation of efficacy, analysis of left ventricule volume by echocardiography transthoracic
Time Frame: at 6 and 12 months
|
Decrease >15% in end-diastolic and/or end-systolic volumes of the left ventricle
|
at 6 and 12 months
|
Evaluation of efficacy, Packer score
Time Frame: at 6 and 12 months
|
The proportion of improved, unchanged and worsened patients in both groups. Patients are considered improved if at the final visit they experienced a favorable change in NYHA functional class or in the patient global assessment (or both) of a prespecified magnitude but did not experience any major adverse clinical events during the course of the trial. Patients are considered worse if they experienced a major clinical event during the planned duration of double-blind treatment or reported worsening of their NYHA class or global assessment at the final visit. Patients are considered unchanged if they are neither improved nor worse. |
at 6 and 12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Romain ESCHALIER, University Hospital, Clermont-Ferrand
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Efficacy
- Heart Failure with reduced ejection fraction (<35%)
- Cardiac Resynchronisation Therapy
- Non specific intraventricular conduction
- Life expectancy expected to exceed one year with a good functional status
- QRS morphology : NICD according to the AHA/ACCF/HRS Recommendations (non-LBBB and non-RBBB):
- QRS duration > 130 ms
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHU-0233
- 2014-A01848-39 (Registry Identifier: 2014-A01848-39)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on CRT implantation
-
University of RochesterNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingHeart Failure | Cardiac Resynchronization Therapy | Right Bundle-Branch Block | His-bundle PacingUnited States
-
Helios Health Institute GmbHHeart Center Leipzig - University HospitalTerminatedChronic Heart FailureGermany
-
Yong-Mei ChaRecruiting
-
Associazione Portatori Dispositivi Impiantabili...RecruitingHeart Failure | Cardiac Resynchronization TherapyItaly
-
Prof. Dr. med. Ingo EitelDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)RecruitingNon-ischemic Dilated CardiomyopathyGermany
-
Abbott Medical DevicesTerminatedHeart Failure | Cardiac ArrhythmiaUnited States, Spain, Germany, Netherlands, Estonia, Canada, Austria, Australia
-
Competence Network for Congenital Heart DefectsCompletedCongenital Heart DefectsAustria, Germany
-
University of RzeszowCompletedChronic Kidney Diseases | Chronic Heart Failure
-
Royal Brompton & Harefield NHS Foundation TrustBoston Scientific CorporationSuspendedHeart Failure | Sleep Disordered BreathingUnited Kingdom
-
Emory UniversityCompletedHeart Failure, Systolic | Left Bundle Branch BlockUnited States